The predictive value of nutritional deficiency in the treatment of patients with locally advanced stomach cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Stomach cancer (SC) is one of the oncological diseases characterized by an extremely unfavorable prognosis. The disease is accompanied by a number of serious complications, including various disorders of metabolic processes, which undoubtedly leads to a deterioration of the general somatic status of patient, adversely affect the tolerability of specialized treatment, quality of life and longevity. Correction and/ or maintenance of nutritional status (NS) in cancer patients is an important factor, which plays a significant role in increasing the effectiveness of antitumor treatment. The evaluation of NS and the programs for correcting its disorders in oncological patients are associated with a number of unresolved issues: in many countries, the protocols for diagnosing and correcting nutritional deficiencies have significant differences; possession of skills and methods for evaluating NS in patients are not mandatory for oncologists; not all of the standards for assessing NS are available for use in routine clinical ractice; there are some difficulties in the implementation of programs for providing formulas necessary for the correction of malnutrition in cancer patients not only in outpatient settings, but often also in the hospital.

Full Text

Restricted Access

About the authors

N. A Brish

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

T. Yu Semiglazova

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikov

Email: tsemiglazova@mail.ru
St. Petersburg, Russia

P. A Zakharova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. V Mishchenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

B. S Kasparov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

S. A Protsenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

G. M Teletaeva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

D. Kh Latipova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. I Semenova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

E. V Tkachenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

Yu. V Alekseeva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

Ya. A Ulyanchenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

L. V Filatova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

V. V Semiglazov

N.N. Petrov National Medical Research Center of Oncology; Pavlova First St. Petersburg State Medical University

Email: tsemiglazova@mail.ru
MD, Associate Professor, Head of the Department, Leading Researcher at the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, N.N. Petrov National Medical Research Center of Oncology; Professor at the Department of Oncology 68, Leningradskaya Street, Pesochny settlement, St. Petersburg 197758, Russian Federation

References

  1. Arends J, Baracos V., Bertz H, et al. ESPEN expert group recommendations for action against cancer related malnutrition. Clinical Nutrition. 2017;36:1187-96. Do: 10.1016/. clnu.2017.06.017.
  2. Wie G.A, Cho Y.A., Kim S.Y, et al. Prevalence and risk factors of malnutrition among cancer patients according to tumor location and stage in the National Cancer Center in Korea. Nutrition. 2010;26(3):263-68. Doi: 101016/. nut.2009.04.013.
  3. Hebuterne X., Lemarie E, Michallet M, et al. Prevalence of malnutrition and current use of nutrition support in patients with cancer. J Parenter Enteral Nutr. 2014;38(2):196-204. doi: 10.1177/0148607113502674.
  4. URL: http://gcoiarc.fr, GLOBOCAN-2018.
  5. Fox J.G., Wang T.C. Inflammation, atrophy, and gastric cancer. J Clin Invest. 2007;117:60-69. doi: 10.1172/JCI30111.
  6. Стуков А.Н., Бланка М.А., Семиглазова Т.Ю., Беляева А.М. Фармакотерапия опухолей. Посвящается памяти Михаила Лазаревича Гершановича. СПб.: Издательство АНО «Вопросы онкологии», 2017. 513 с. [Stukov A.N., Blanc M.A., Semiglasova T.Yu, Belyaeva A.M. Pharmacotherapy of tumors. Dedicated to the memory of Mikhail Lazarevich Gershanovich. St. Petersburg, 2017. (In Russ.)].
  7. FerlayJ., Shin H.R., Bray F., et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base [Internet]. Lyon, France: International Agency for Research on Cancer. 2010. 10 p.
  8. Cunningham D., Allum W.H., Stenning S.P, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355: 11-20.
  9. Ychou М., Boige V., Pignon J.P., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715-21. Doi: 10.1200/ JCO.2010.33.0597.
  10. Al-Batran S.E., Homann N., Schmalenberg H., et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. J Clin Oncol. 2017;35(15):4004. doi: 10.1200/JCO.2017.35.15_suppl.4004.
  11. Schuhmacher C., Gretschel S., Lordick F., et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210-18. doi: 10.1200/JC0.2009.26.6114.
  12. Tan B.H., Brammer K., Randhawa N., et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol. 2015;41:333-38. Doi: 10.1016/j. ejso.2014.11.040.
  13. Cox S., Powell C., Carter B., et al. Role of nutritional status and intervention in oesophageal cancer treated with definitive chemoradiotherapy: outcomes from SCOPE1. Br J Cancer. 2016;115:172-77. doi: 10.1038/bjc.2016.129.
  14. Mirkin K.A., Luke F.E., Gangi A., et al. Sarcopenia related to neoadjuvant chemotherapy and perioperative outcomes in resected gastric cancer: a multi-institutional analysis. J Gastrointest Oncol. 2017;8(3):589-95. Doi: 10.21037/ jgo.2017.03.02.
  15. Palmela C, Velho S., Agostinho L., et al. Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer. J Gastric Cancer. 2017;17(1):74-87. Doi: 10.5230/ jgc.2017.17.e8.
  16. Kawamura T, Makuuchi R., Tokunaga M., et al. Long-Term Outcomes of Gastric Cancer Patients with Preoperative Sarcopenia. Ann Surg Oncol. 2018;25(6):1625-32. doi: 10.1245/s10434-018-6452-3.
  17. Awad S., Tan B.H., Cui H., et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr. 2012;31:74-7. Doi: 10.1016/j. clnu.2011.08.008.
  18. Prado C.M., Baracos V.E., McCargar L.J., et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13:3264-68. Doi: 10,1158/1078-0432.CCR-06-3067.
  19. Huang D.D., Zhou C.J., Wang S.L., et al. Impact of different sarcopenia stages on the postoperative outcomes after radical gastrectomy for gastric cancer. Surgery. 2017;161:680-93. doi: 10.1016/j.surg.2016.08.030
  20. Chen F.F., Zhang F.Y., Zhou X.Y., et al. Role of frailty and nutritional status in predicting complications following total gastrectomy with D2 lymphadenectomy in patients with gastric cancer: a prospective study. Langenbecks Arch Surg. 2016;401:813-22. doi: 10.1007/s00423-016-1490-4
  21. Zhuang C.L., Huang D.D., Pang W.Y., et al. Sarcopenia is an independent predictor of severe postoperative complications and long-term survival after radical gastrectomy for gastric cancer: analysis from a large-scale cohort. Medicine (Baltimore). 2016;95:e3164. Doi: 10.1097/ MD.0000000000003164.
  22. Wang S.L., Zhuang C.L., Huang D.D., et al. Sarcopenia adversely impacts postoperative clinical outcomes following gastrectomy in patients with gastric cancer: a prospective study. Ann Surg Oncol. 2016;23:556-64. doi: 10.1245/s10434-015-4887-3.
  23. Fukuda Y, Yamamoto K., Hirao M., et al. Sarcopenia is associated with severe postoperative complications in elderly gastric cancer patients undergoing gastrectomy. Gastric Cancer. 2016;19:986-93. doi: 10.1007/s10120-015-0546-4.
  24. Tamandl D., Paireder M., Asari R., et al. Markers of sarcopenia quantified by computedtomography predict adverse long-term outcome in patients withresected oesophageal or gastro-oesophageal junction cancer. Eur Radiol. 2016;26(5):1359-67. doi: 10.1007/s00330-015-3963-1.
  25. Miyamoto Y, Baba Y, Sakamoto Y, et al. Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer. Ann Surg Oncol. 2015;22(8):2663-68. Doi: 10.1245/ s10434-014-4281-6.
  26. Okumura S., Kaido T., Hamaguchi Y, et al. Impact of the preoperative quantity and quality of skeletal muscle on outcomes after resection of extrahepatic biliary malignancies. Surgery.2016;159(3):821-33. Doi: 10.1016/j. surg.2015.08.047.
  27. Levolger S., van Vledder M.G., Muslem R, et al. Sarcopenia impairs survival in patients with potentially curable hepatocellular carcinoma. J Surg Oncol. 2015;112(2):208-13. Doi: 10.1002/ jso.23976.
  28. Huang D.D., Chen X.X., Chen X.Y., et al. Sarcopenia predicts 1-year mortality in elderly patients undergoing curative gastrectomy for gastric cancer: a prospective study. J Cancer Res Clin Oncol. 2016;142:2347-56. Doi: 10.1007/ s00432-016-2230-4.
  29. Li X.T., Tang L., Chen Y., et al. Visceral and subcutaneous fat as new independent predictive factors of survival in locally advanced gastric carcinoma patients treated with neo-adjuvant chemotherapy. J Cancer Res Clin Oncol. 2015;141:1237-47. doi: 10.1007/s00432-014-1893-y.
  30. Lou N., Chi C.H., Chen X.D., et al. Sarcopenia in overweight and obese patients is a predictive factor for postoperative complication in gastric cancer: a prospective study. Eur J Surg Oncol. 2017;43:188-95. doi: 10.1016/j.ejso.2016.09.006.
  31. Nishigori T, Tsunoda S., Okabe H., et al. Impact of sarcopenic obesity on surgical site infection after laparoscopic total gastrectomy. Ann Surg Oncol. 2016;23:524-31. doi: 10.1245/s10434-016-5385-y.
  32. Heymsfield S.B., Lohman T.G., Wang Z., et al. Human body composition. Champaign, IL: Human Kinetics, 2005. 533 p.
  33. Русакова Д.С., Щербакова М.Ю., Гаппарова К.М. и др. Современные методы оценки состава тела. Гастроэнтерология. 2012;8:71-81.
  34. ESMO Handbook. Nutrition and Cancer. 2014. https://oncologypro.esmo.org/Education-Library/ Handbooks/Nutrition-and-Cancer
  35. Патент РФ №2012129472/14, 11.07.2012. Способ определения прогрессии рака органов брюшной полости. Патент России № 2340950. 10.01.2014 Бюл. № 1. Янковская П.А., Кораблева Н.П., и др. [Patent of the Russian Federation №2012129472/14, 11.07.2012. Method for determining the progression of cancer of the abdominal organs. Patent of Russia No. 2340950. 01/10/2014 Byul. № 1. Yankovskaya PA., Korableva N.P, etal.(in Russ.)].
  36. Руковоство по клиническому питанию. Под ред. проф. В.М. Луфта. СПб.: Арт-Экспресс, 2016. 484 с. [Guide to clinical nutrition. Ed. Luft V.M. St. Petersburg: Art-Ekspress, 2016. 484p. (In Russ.)].
  37. Нутритивная поддержка при онкологических заболеваниях. Протоколы клинических рекомендаций Общества специалистов поддерживающей терапии в онкологии (RASSC). 2017. [Nutritional support for cancer. Protocols of clinical recommendations of the Society of Supportive Care Specialists in Oncology (RASSC). 2017. (In Russ.)].
  38. Клинические рекомендации Национальной ассоциации парентерального и энтерального питания (Россия).[Clinical recommendations of the National Association of Parenteral and Enteral Nutrition. (In Russ.)]. URL: http://rspen.ru/web/ spravochnik/klinicheskie-rekomendacii/
  39. August D.A., Huhmann M.B. A.S.PE.N. Clinical Guidelines: Nutrition Support Therapy During Adult Anticancer Treatment and in Hematopoietic Cell Transplantation. JPEN. 2009;33(5):472-500. doi: 10.1177/0148607109341804.
  40. Сытов А.В., Лейдерман И.Н., Ломидзе С.В. и др. Практические рекомендации по нутритивной поддержке онкологических больных.
  41. Постановление Правительства Российской Федерации от 08 декабря 2017 года № 1492

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies